|
gentronix provides services and solutions that help companies optimize the development of drugs and other chemicals, by reducing rates of attrition due to toxicity and ensuring safer products across a wide range of chemistry driven industries.
Our primary focus is on providing better hazard identification assays for genotoxicity through the use of our patented human cell GADD45a reporter assays GreenScreen HC® and BlueScreen HCTM. Gentronix provides contract services for genotoxicity in these and related assays including Comet and Micronucleus tests, as well as a wide range of ADME and predictive toxicity endpoints.
Reducing attrition rates due to toxicity concerns is critical to increasing the success of drug discovery projects. Identifying toxicity liability early allows valuable resources to be directed towards compounds more likely to advance to candidate selection and on to clinical evaluation.
Currently over 90 pharmaceutical and fine chemical companies in 16 countries have used the GreenScreen HC assay data as part of their genotoxicity profiling strategy.
|